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Abstract
Background and purpose: We report the radiographic response rate of SBRT compared to conventional fractionated
radiotherapy (CF-EBRT) for thoracic, abdominal, skin and soft tissue RCC lesions treated at our institution.
Material and methods: Fifty three lesions where included in the study (36 SBRT, 17 CF-EBRT), treated from 2004 to
2014 at our institution. We included patients that had thoracic, skin & soft tissue (SST), and abdominal metastases of
histologically confirmed RCC. The most common SBRT fractionation was 50 Gy in 5 fractions.
Results: The median time of follow-up was 16 months (range 3–97 months). Median BED was 216.67 (range
66.67–460.0) for SBRT, and 60 (range 46.67–100.83) for CF-EBRT. Median radiographic local control rates at 12,
24, and 36 months were 100, 93.41, and 93.41 % for lesions treated with SBRT versus 62.02, 35.27 and 35.27 % for those
treated with CF-EBRT (p < 0.001). Predictive factors for radiographic local control under univariate analysis included
BED≥ 100 Gy (HR, 0.048; 95 % CI, 0.006–0.382; p = 0.005), dose per fraction≥ 9 Gy (HR, 0.631; 95 % CI, 0.429–0.931;
p = 0.021), and gender (HR, 0.254; 95 % CI, 0.066–0.978; p = 0.048). Under multivariate analysis, there were no
significant predictors for local control. Toxicity rates were low and equivalent in both groups, with no grade 4 or
5 side effects reported.
Conclusions: SBRT is safe and effective for the treatment of RCC metastases to thoracic, abdominal and
integumentary soft tissues. Radiographic response rates were greater and more durable using SBRT compared to
CF-EBRT. Further prospective trials are needed to evaluate efficacy and safety of SBRT for RCC metastases.
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Background
The global annual incidence of renal cell carcinoma
(RCC) is nearly 209,000 cases, killing over 100,000
people each year [5]. The majority of these patients
present with isolated disease, however, about 30 % of
these patients recur after treatment either locally or,
more frequently, distantly and about the same percent-
age present with metastatic spread at the time of diagno-
sis [18]. In the setting of metastatic disease, RCC most
commonly spreads to the lung, accounting for approxi-
mately 60 % of metastatic cases. Hepatic involvement
occurs in about 20 % of cases. Prognosis is generally fa-
vorable for patients with non-metastatic disease however
the two-year survival in patients with widespread disease
is much worse (10–20 %) [18].
As patients with RCC continue to live longer given the
rapid advances seen in systemic treatment for RCC with
targeted agents (eg, tyrosine kinase inhibitors (TKIs),
vascular endothelial growth factor (VEGF) inhibitors,
and mTOR inhibitors), localized treatment of enlarging
or anatomically problematic masses is becoming increas-
ingly utilized to further lengthen and improve quality of
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life [4, 6, 11]. In patients with oligo-metastatic disease,
surgical resection has been employed with promising re-
sults. For instance, Loizzi et al. demonstrated improved
overall survival, four-year survival of 50 %, after surgi-
cally resecting easily accessible RCC lung lesions [9].
In addition to surgical therapy, traditionally fractionated
radiotherapy has been used to treat metastatic disease des-
pite the traditional thinking of RCC being “radioresistant”.
However, over the past decade, increased use of hypofrac-
tionation with stereotactic body radiotherapy (SBRT) has
allowed clinicians to accurately target lesions and deliver
more ablative doses. Efficacy of SBRT has been demon-
strated in multiple metastatic sites, with local control rates
above 90 % [13, 17, 18]. Bextracranial stereotactic radiother-
apyextracranial stereotactic radiotherapysingle-institution
studies demonstrating high local control rates using SBRT,
we sought to directly compare the radiographic outcomes
of RCC lesions between traditional or conventional frac-
tionation (CF-EBRT) and SBRT in our institution to en-
hance the dataset analyzing the radiosensitivity of RCC.
Additionally, the goal of this study was to further define the
most effective radiation delivery by estimating a minimum
dose, either fraction size or biologic effective dose (BED)
cutoff, needed to achieve long term local control.
Materials and methods
Patients were retrospectively identified by searching an
institutional database of patients treated with radiation
for RCC at the University of Colorado Cancer Center be-
tween December 2005 and May 2014. This study was ap-
proved by the University of Colorado Institutional Review
Board. We included patients that had pathological con-
firmation of primary RCC and radiographic evidence of
metastatic lesions. All patients included had a minimum
follow up of 3 months post radiation therapy. Sites of me-
tastasis were grouped into thorax, skin & soft tissue (SST),
and abdomen.
Patients were treated with SBRT using intensity modu-
lated radiotherapy (IMRT) planning. All patients treated
with SBRT underwent treatment simulation prior. Simu-
lation scans were CT based, with 3 mm slice thickness.
In the more recent years, lesions with tumor motion
underwent 4D imaging with abdominal compression. Pa-
tients were supine and immobilized with a vac-loc or
alphacrade. IV contrast use was at the discretion of the
treating physician. For treatment planning, the gross
tumor volume (GTV) was considered equal to the clinical
target volume (CTV). An internal target volume (ITV)
was generated for lesions with motion who underwent 4D
imaging, which was then expanded to the planned tumor
volume (PTV). The PTV expansion depended on the
treatment site and physician discretion. CF-EBRT were
treated with simple 2D planning, 3D, and at times inten-
sity modulated radiotherapy (IMRT) if there were nearby
critical organs at risk nearing maximum dose tolerance.
All SBRT cases underwent daily image guidance (IGRT)
during treatment.
Patients were evaluated for radiographic response after
treatment. Radiographic complete response was defined
as: no evidence of disease in the treatment volume by in-
terpretation of available Fludeoxyglucose-Positron emis-
sion tomography/computed tomography (FDG-PET/CT),
Magnetic Resonance Imaging (MRI), or computed tomog-
raphy (CT) scans 3 months after SBRT. Stable disease was
defined as absence of marked change or increase in the
treated lesion. Partial response was defined as not meeting
the criteria for complete response or stable disease. Pa-
tients were labeled as radiographic responders if they had
a complete response, partial response and/or stable dis-
ease after radiation. Treated metastasis control was de-
fined as the time from the last day of radiation treatment
to failure at the treated site or last follow-up in living pa-
tients without evidence of recurrence or progression. Use
of the Response Evaluation Criteria in Solid Tumors
(RECIST) was not used due to difficulty assessing paren-
chymal changes common after SBRT, especially to sites
treated to 20 Gy or higher. Instead failure at the treated
site was scored as lesions that experienced a complete,
partial or stable response after therapy; all other lesions
that had an increase in standardized uptake value
(SUV) on PET or expansion of a solid mass compared
to prior CT-based imaging. All scans were verified by a
certified radiologist.
Univariate survival analysis was performed with the
log-rank test, with Cox proportional hazards regression
used to estimate hazard ratios (HR). Multivariate Cox
regression analysis was performed to evaluate the as-
sociation between clinical factors and LRC with a sig-
nificance level of p < 0.05. The independent variables
considered were total dose, number of fractions, dose
per fraction, biologic effective dose (BED), site (thorax
vs other), histology (clear cell vs other), GTV, PTV,
gender, age, time from initial diagnoses to end of radi-
ation therapy, smoking status, extensive disease (as de-
fined by greater than five metastatic lesions), and
systemic therapy pre- and post-radiation. CTCAE ver-
sion 4.0 was used for scoring toxicity. Patients were
censored at the time of death and lost to follow up.
Results
Patient and treatment characteristics
In total, 34 patients were selected, with 53 treated le-
sions; 36 (68 %) lesions were treated with SBRT and 17
(32 %) with conventional fractionation (CF-EBRT). The
study cohort was followed for a median time of 16 months
(range 3–97 months) and the median time for first follow-
up was similar in both groups. The majority of patients
were male (59 %) with clear cell histology (91 %). The
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most common SBRT fractionation was 50 Gy given in 5
fractions (10 Gy per fraction); the most common CF-
EBRT treatment was 40 Gy in 10 fractions (4 Gy per frac-
tion); 47 % (N = 8) of CF-EBRT were treated with pallia-
tive intent (20 Gy in 5 fractions/30 Gy in 10 fractions)
(Table 1). The majority of lesions treated were located in
the thorax [lung parenchyma (N = 23), hilar and medias-
tinal lymph nodes (N = 12), and pericardium (N = 1)].
Eight lesions were located in skin/soft tissue [skin/soft tis-
sue extremity (N = 5), parotid (N = 1), gingiva (N = 1), and
tongue (N = 1)], and nine lesions treated were within the
abdomen [abdominal lymph nodes (N = 3), kidney (N = 3),
pancreas (N = 2), and liver (N = 1)]. Median number of le-
sions treated per patient was 1 (range 1–3). There was no
difference between median tumor size between the two
groups (SBRT - 21 mm (4–87) and CF-EBRT - 23 mm
(15–57)) after t-test comparison (p = 0.357). Median BED
was 216.67 (range 66.67–460.0) and 60 (range 46.67–
100.83) for SBRT and CF-EBRT respectively. The majority
of patients were on systemic therapy before (72 %) and
after radiation (57 %) (Table 2).
Response rates
For all patients combined, radiation therapy provided a
median 12 and 24 months treated metastasis control
rate of 87.45 and 72.16 %, respectively. The median 12
and 24 months treated metastasis control rate in SBRT
treated lesions were 100 and 93.41 % versus 62.02 and
35.27 % in the CF-EBRT (Fig. 1). Radiographic local con-
trol rates were significantly different (p < 0.001). There
was no difference in overall survival between the two
groups (p = 0.831) (Fig. 2).
Predictors for local control
When combining all patients included in the study
(SBRT and CF-EBRT), predictive factors for radiographic
local control under univariate analysis included BED ≥
100 Gy (HR, 0.048; 95 % CI, 0.006–0.382; p = 0.005) and
a dose per fraction ≥ 9 Gy (HR, 0.631; 95 % CI, 0.429–
0.931; p = 0.021). Another predictor included gender
(HR, 0.254; 95 % CI, 0.066–0.978; p = 0.048). Non-
significant predictive factors for radiographic local control
included age, lesion location, total dose, smoking, and sys-
temic therapy before or after treatment. GTV and PTV
size were non-significant for SBRT patients (p = 0.429).
All significant predictors under univariate analysis did not
maintain significance under multivariate analysis (Ta-
bles 3, 4 and 5). Toxicity rates were low and equivalent
in both groups, with no grade 4 or 5 side effects re-
ported (Table 6).
Discussion
As assessment of radiation therapy’s effectiveness in
RCC is dependent on the BED administered and this
work provides an important comparison between SBRT
and EBRT in this regard. Presently, the majority of SBRT
data for RCC tumors focuses on osseous metastatic sites,
with less data on non-bony locations. In the era of SBRT,
our findings in addition to other single institutional
studies, have demonstrated long-term radiographic local
control rates for RCC lesions with the use of SBRT in-
stead of CF-EBRT. The data presented here is an update
of prior data published at our institution, which had in-
cluded 25 lesions (in 13 RCC patients) treated with
SBRT; the results here, which includes more lesions with
longer follow up, confirms our prior findings that ag-
gressive SBRT can result in good local control rates.
Additional institutions have also demonstrated similar
results [12, 18]. Wersall and colleagues published their
results and demonstrated local control rates above 90 %
Table 1 Patient and clinical characteristics
Variable Value
Total Number of Patients 34
Age
Median (range) 68 (27–84)
Sex
Male 20 (59 %)
Female 14 (41 %)
KPS
Median (range) 90 (60–100)
Histology
Clear Cell 48 (91 %)
Papillary 4 (7 %)
Not Otherwise Specified 1 (2 %)
Treatment Patterns
Treated with SBRT 36 (68 %)
25 Gy/1 fx 2
30 Gy/2 fx 1
54 Gy/4 fx 1
24–60 Gy/3 fx 15
25–50 Gy/5 fx 14
40 Gy/8 fx 1
50 Gy/10 fx 2
Treated with CF-EBRT 17 (32 %)
20 Gy/5 fx 5
32 Gy/8 fx 1
30–40 Gy/10 fx 8
45 Gy/13 fx 1
45 Gy/15 fx 1
55 Gy/22 fx 1
KPS karnofsky performance status, SBRT stereotactic body radiotherapy,
CF-EBRT conventional fractionated external beam radiotherapy
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in their series of RCC treated sites including lung,
renal bed, lymph nodes, and adrenal gland; 30 % of
patients had complete regression of lesions within 3–
36 months, 60 % with partial volume reduction or no
change after a median follow-up of 37 months, 2 %
had progression, and 8 % were non-evaluable due to
early death or atelectasis 18]. Svedman et al. demon-
strated very similar findings with a 98 % local control
rate. Complete response in their cohort was observed
in 21 % of the patients and 58 % of the patients had
a partial volume reduction or local stable disease after
a median follow-up of 52 months [16]. These findings
are similar to our results, with local control rates of
90 % or higher. Taken together, these single institu-
tional studies suggest that SBRT may be more effect-
ive at controlling RCC lesions, which were once
thought to be radioresistant with the use of lower
dose, conventional therapy.
Fig. 1 Kaplan-Meier curve demonstrating actuarial radiographic control rates between SBRT and CF-EBRT
Table 2 Treatment characteristics between SBRT and CF-EBRT
Variable SBRT (n = 36) CF-EBRT (n = 17)
Location, n (%)
Thorax 27 (75 %) 9 (53 %)
Skin & Soft Tissue 3 (8.3 %) 5 (29 %)
Abdomen 6 (16.7 %) 3 (18 %)
Median Dose Per Fraction
(range, Gy)
10 (5–25) 4 (2.5–4)
Median Tumor Size (range, mm)* 21 (4–87) 23 (15–57)
Gross Tumor Volume (GTV) (range, cm3) 5.14 (0.93–184.07) -
Planned Tumor Volume (PTV) (range, cm3) 20.01 (6.00–295.51) -
Biological Effective Dose (BED) (range) 216.67 (66.67–460) 60.00 (46.67–100.83)
Systemic Therapy Prior to Radiation, n (%)
Yes 26 (72 %) 12 (71 %)
No 10 (28 %) 5 (29 %)
Systemic Therapy After Radiation, n (%)
Yes 20 (55 %) 10 (59 %)
No 16 (45 %) 7 (41 %)
GTV gross tumor volume, PTV planned tumor volume, BED biologic effective dose
*As determined from the greatest tumor dimension by pre-treatment radiographic imaging. No difference was found between the two groups via t-test
comparison (p = 0.357)
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The results presented here also illustrate predictors for
local response included BED ≥ 100 and fraction size ≥
9 Gy. These findings are again supported by earlier re-
sults published at our institution evaluating the use of
SBRT and doses needed to establish effective control
rates for metastatic melanoma and RCC [1, 15]. Sti-
nauer and colleagues included 25 RCC lesions treated
with 40–50 Gy in 5 fractions or 42–60 Gy in 3 fractions
and had a local control rate of 88 % at 18 months [15].
Predictors of in-field local control included BED >
100 Gy and fraction size > 11 Gy, comparable to our
findings. BED has been confirmed to be a strong pre-
dictive factor in many other studies, including several
Radiation Therapy Oncology Group (RTOG) clinical
trials evaluating local control rates with SBRT [10, 13,
17]. Radiobiologically, the higher dose per fraction with
SBRT-based treatments has been shown to provide im-
proved local control over standard fractionation. As the
survival and proliferation of tumor cells are directly
dependent on the blood supply, SBRT has been shown
to have a direct effect on tumor vasculature. Hypoxia
can increase the expression of vascular endothelial
growth factors, which is associated with higher grade
tumors and metastatic disease [3]. High-dose single frac-
tionation at 10 Gy or higher has been shown to cause
severe vascular damage in human tumor xenografts or
Fig. 2 Kaplan-Meier curve demonstrating Overall Survival Rates between SBRT and CF-EBRT
Table 3 Univariate and multivariate analysis for radiographic predictors of Local Control (LC) for all patients
Univariate Multivariate
Variable P-value HR (95 % CI) P-value
Total Dose (Gy) 0.001* 0.999 (0.998 to 1.001) 0.209
Number of Fractions 0.189 1.004 (0.849 to 1.185) 0.966
Dose per Fractions (≥9 Gy) 0.021 0.726 (0.469 to 1.124) 0.153
BED (100 Gy) 0.005* 0.264 (0.022 to 3.119) 0.293
Site (Thorax vs Other) 0.185 1.941 (0.515 to 7.323) 0.329
Time from Primary Diagnosis 0.318 0.996 (0.980 to 1.012) 0.663
Male Gender 0.048 0.481 (0.120 to 1.915) 0.301
Age 0.610 0.990 (0.916 to 1.071) 0.816
Smoker 0.123 0.276 (0.058 to 1.311) 0.107
Greater than 5 Metastatic Lesions 0.808 0.674 (0.170 to 2.673) 0.577
Pre-Radiation Systemic Therapy 0.517 2.299 (0.605 to 8.724) 0.223
Post-Radiation Systemic Therapy 0.332 0.201 (0.038 to 1.037) 0.056
BED biologic effective dose, HR hazard ratio, CI confidence interval
*-Statistically significant values
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animal tumors [2, 8]. SBRT, coupled with targeted agents
including vascular endothelial growth factor (VEGF) in-
hibitors and TKIs, may have both a synergistic local effect
in addition to systemic effect and is currently being stud-
ied. Additionally, the vascular injury and ensuing chaotic
intratumor environment such as hypoxic, acidic and
nutritionally-deprived environment caused by high-dose
fraction SBRT, may significantly hinder the repair of radi-
ation damage [14]. RCC has several hypothesized mecha-
nisms for radiation resistance with EBRT. One may be a
mutation or silencing of the von Hippel-Lindau (VHL)
gene which is present in over 50 % of cases and is thought
to lead in the accumulation of hypoxic-inducible factor 1-
alpha (HIF1A), which then creates angiogenesis leading to
further tumor growth and potential disease spread [7]. As
described, the mechanism in which SBRT can cause endo-
thelial apoptosis with single high dose treatments may
help overcome this pathway.
Currently, the role of systemic therapy in RCC con-
tinues to improve with more targeted therapies, provid-
ing patients with improved survival and quality of life.
Because of this, SBRT is positioned to play a valuable
role in providing not only high local control rates but
prolonged duration of symptomatic control from months
to years. This in turn could translate into both symp-
tomatic relief for the patients and improved survival,
especially in those with oligo-progressive disease. In
addition, new agents are constantly being developed
Table 4 Univariate and multivariate analysis for radiographic predictors of Local Control (LC) for SBRT patients
Univariate Multivariate
Variable P-value HR (95 % CI) P-value
Total Dose (Gy) 0.772 0.999 (0.997 to 1.001) 0.608
Number of Fractions 0.789 1.086 (0.528 to 2.233) 0.822
Dose per Fractions (≥9 Gy) 0.474 0.835 (0.528 to 1.319) 0.442
BED (100 Gy) 0.534 0.988 (0.957 to 1.019) 0.461
Site (Thorax vs Other) 0.961 0.948 (0.915 to 1.012) 0.957
GTV 0.429 0.958 (0.921 to 1.091) 0.967
PTV 0.429 - -
Time from Primary Diagnosis 0.491 1.224 (0.645 to 2.320) 0.537
Age 0.701 1.063 (0.885 to 1.277) 0.513
Smoker 0.965 - -
Greater than 5 Metastatic Lesions 0.963 - -
Pre-Radiation Systemic Therapy 0.959 - -
Post-Radiation Systemic Therapy 0.961 - -
BED biologic effective dose, GTV gross tumor volume, HR hazard ration, CI confidence interval
Table 5 Univariate and multivariate analysis for radiographic predictors of Local Control (LC) for CF-EBRT patients
Univariate Multivariate
Variable P-value HR (95 % CI) P-value
Total Dose (Gy) 0.025* 0.994 (0.986 to 1.003) 0.216
Number of Fractions 0.114 0.872 (0.698 to 1.090) 0.232
Dose per Fractions (≥9 Gy) 0.950 0.729 (0.195 to 2.725) 0.640
BED (100 Gy) 0.017* 3.94 (0.028 to 2.345) 0.325
Site (Thorax vs Other) 0.867 1.579 (0.404 to 6.173) 0.513
Time from Primary Diagnosis 0.714 0.987 (0.961 to 1.015) 0.386
Male Gender 0.653 1.003 (0.244 to 4.128) 0.995
Age 0.560 0.953 (0.860 to 1.056) 0.366
Smoker 0.172 - -
Greater than 5 Metastatic Lesions 0.933 0.886 (0.216 to 3.623) 0.867
Pre-Radiation Systemic Therapy 0.536 2.340 (0.586 to 9.345) 0.231
Post-Radiation Systemic Therapy 0.417 0.206 (0.035 to 1.242) 0.086
BED biologic effective dose, HR hazard ration, CI confidence interval
*-Statistically significant values
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that may have a synergistic effect with SBRT and will
need to be evaluated in clinical trials.
Our study is limited by its retrospective nature, short-
term follow up which may have underestimated disease
recurrence rates and long term toxicity, and variability
in treatment (specifically, fractionation size and total
dosage). A common weakness in these studies is the in-
herent selection bias that may exist as patients who are
treated with SBRT may have had less systemic burden,
lower comorbidities, and better overall performance sta-
tus. However, as our endpoints focuses on local radio-
graphic control, it is unlikely these factors contribute
significantly to our findings. Further, this study includes
data over a long period of time, where technical and sys-
temic treatment approaches have vastly changed. Add-
itionally, due to the relative small numbers of lesions
included in this study, subset analysis of each group was
difficult. The majority of our patients who underwent
SBRT were asked to hold their systemic therapies such
as TKIs the day prior to starting SBRT and resumed the
day after completion; future studies would need to
evaluate toxicity of combining TKIs and other targeted
agents with SBRT. Lastly, long term follow up of how
these treatments influence the overall survival of pa-
tients with RCC is unknown and worthy of prospective
follow up.
To conclude, based on our results and emerging data
from other investigators, a difference in efficacy between
SBRT and CF-EBRT is emerging in the treatment of
RCC. Future prospective studies are needed to evaluate
efficacy and toxicity of SBRT in the setting of oligometa-
static disease for RCC, especially in the setting of newer
immune-modulating therapies. With the current pub-
lished single institutional studies available, SBRT appears
to significantly improve local control rates and symptom
relief for metastatic RCC to the bone and should be con-
sidered for these patients.
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